Federal Circuit Revives Astellas Pharma’s Overactive Bladder Patent in Key Legal Ruling

The Federal Circuit recently vacated a lower court’s decision that invalidated Astellas Pharma’s patent for an overactive bladder medication based on claims related to a natural law. The higher court determined that the lower court’s ruling was improper since the generic drug manufacturers accused of infringement did not present that argument. This turn of events marks a significant development in patent litigation, particularly concerning the application of natural law principles in pharmaceutical patents. For more detailed coverage on this case, visit the original report from Law360.